Current randomized controlled data ([1][1] , [2][2]) demonstrate the safety and efficacy of 6 cycles of [177Lu]Lu-PSMA-617 therapy in men with metastatic castration-resistant prostate cancer. In our first phase 2 trial ([3][3]), 15 of 30 patients received additional cycles; 11 (73%) had a subsequent
不倦
杳鸢
请叫我风吹麦浪
劲秉
风语村
痴情的博超
kingwill
pluto
一一
来日可追
科研小民工
cdercder
maox1aoxin
迟大猫
YY
犇骉
火星上的菲鹰
sutharsons
黎幻枫
爱静静
皖公网安备34019202002308
